Ashford Capital Management Inc. Reduces Holdings in Progyny, Inc. (NASDAQ:PGNY)

Ashford Capital Management Inc. lessened its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 40.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,090 shares of the company's stock after selling 158,134 shares during the quarter. Ashford Capital Management Inc. owned 0.27% of Progyny worth $3,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. RiverPark Advisors LLC lifted its stake in shares of Progyny by 9.6% in the second quarter. RiverPark Advisors LLC now owns 5,408 shares of the company's stock worth $155,000 after buying an additional 474 shares in the last quarter. Arizona State Retirement System boosted its stake in Progyny by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 24,313 shares of the company's stock valued at $696,000 after purchasing an additional 609 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in shares of Progyny by 1.1% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 70,717 shares of the company's stock worth $2,023,000 after purchasing an additional 787 shares in the last quarter. Quarry LP lifted its holdings in shares of Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company's stock valued at $25,000 after purchasing an additional 836 shares in the last quarter. Finally, Creative Planning increased its holdings in Progyny by 13.8% in the 2nd quarter. Creative Planning now owns 10,564 shares of the company's stock worth $302,000 after buying an additional 1,283 shares in the last quarter. Institutional investors own 94.93% of the company's stock.

Progyny Stock Down 0.6 %

NASDAQ:PGNY traded down $0.10 on Tuesday, reaching $15.74. 943,235 shares of the company's stock traded hands, compared to its average volume of 1,398,532. The firm has a market cap of $1.34 billion, a PE ratio of 27.31, a P/E/G ratio of 1.66 and a beta of 1.35. The stock has a 50-day simple moving average of $15.61 and a 200-day simple moving average of $21.63. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to analysts' expectations of $296.85 million. During the same period in the previous year, the business posted $0.16 earnings per share. The business's revenue was up 2.0% on a year-over-year basis. On average, equities analysts anticipate that Progyny, Inc. will post 0.59 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PGNY shares. JMP Securities lowered shares of Progyny from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 19th. Leerink Partners cut their target price on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research report on Thursday, September 19th. Bank of America dropped their price target on Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $17.00 price objective (down previously from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Progyny has an average rating of "Hold" and a consensus target price of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.